Schering-Plough, Merck's Vytorin misses study goal

Monday, July 21, 2008 - 16:07 in Health & Medicine

TRENTON, N.J. (AP) -- In the latest disappointment for cholesterol pill Vytorin, a major European study in patients with heart valve disease found the drug didn't prevent worsening of the disease or lower the need for valve surgery, sending its makers' stock plunging....

Read the whole article on AP Health

More from AP Health

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net